Opportunity Radar

← Back to search

Grant

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

View on Grants.gov ↗ Sign in to save

Type
Grant
Notice type
CA
Agency
National Institutes of Health
Sub-agency
HHS-NIH11
Solicitation #
RFA-NS-28-012
Posted
Nov 3, 2026
Response due
Oct 10, 2028
Archive date
Dec 9, 2028
CFDA / Assistance listing
93.866,93.NS1
Award ceiling
$2,500,000
Total program funding
$6,000,000
Contact
nindsdonadrd@mail.nih.gov
Source
Grants.gov

Description

This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations.ADRD include Frontotemporal Dementia (FTD); Lewy Body Dementias (LBD), including Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD); Vascular Contributions to Cognitive Impairment and Dementia (VCID); and Multiple Etiology Dementias (MED).

Similar open opportunities